Library / regulatory-reference
Slovakia: State Institute for Drug Control (SUKL)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
The State Institute for Drug Control, known by its Slovak initials SUKL, is Slovakia's national regulatory authority for medicines and medical devices.
Slovakia's market sits inside the European single market, and the institute works within the European regulatory network while overseeing a market with a strong generic-manufacturing presence.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and establishments are licensed and inspected by the institute.
Post-market work includes safety monitoring and recalls within the European alert network, and Slovakia's reimbursement rules, with mandatory price referencing, shape how authorized products reach patients.
Regional and international role
The institute is an active member of the European regulatory network, contributing to shared scientific and inspection work.
Its pricing and reimbursement referencing practice makes Slovakia influential in the European debate on medicine prices, since many countries reference its official prices.
Using this profile
The institute publishes regulations, registers and alerts in Slovak, with English material, through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Slovakia illustrates the network-member regulator whose price list carries weight far beyond its borders.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.